Clik here to view.
Astex Pharmaceuticals Announces U.S. Food and Drug Administration (FDA)...
PLEASANTON, Calif. Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Japan, today announced that the U.S. FDA has accepted for Priority Review its...
View ArticleClik here to view.
Foundation Medicine and Chugai Announce Partnership with National Cancer...
CAMBRIDGE, Mass. & TOKYO Foundation Medicine, Inc. and Chugai Pharmaceutical, Ltd. (TOKYO: 4519) have entered into an agreement with the National Cancer Center (NCC) for the use of...
View ArticleClik here to view.
Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver...
View ArticleClik here to view.
CANbridge Pharmaceuticals Completes US$98 Million Series D Financing
BEIJING CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced the completion...
View ArticleClik here to view.
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug...
View ArticleClik here to view.
Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for...
PRINCETON, N.J. Bristol-Myers Squibb Company (NYSE: BMY) today announced Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Opdivo (nivolumab) for the treatment of patients with...
View ArticleClik here to view.
Genetron Health and InnoCare Team Up In Partnership To Accelerate the...
BEIJING Genetron Holding Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, has announced a strategic partnership with Beijing InnoCare Pharma...
View ArticleClik here to view.
Takeda Announces U.S. FDA Grants Priority Review for Supplemental New Drug...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the...
View ArticleClik here to view.
武田宣布美国FDA授予ALUNBRIG® (brigatinib)作为ALK+转移性非小细胞肺癌一线治疗的补充新药申请优先审理
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)今天宣布，美国食品药品管理局(FDA)已授予该公司ALUNBRIG...
View ArticleClik here to view.
武田薬品、ALK陽性転移性非小細胞肺がんに対するファーストライン治療薬としてのALUNBRIG®（ブリガチニブ）の適応追加申請を米国FDAが優先審査に指定と発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho’s...
HAYWARD, Calif. Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and Taiho Pharmaceutical Co. Ltd., (“Taiho”),...
View ArticleClik here to view.
New Cancer Treatment Developed at NTHU
HSINCHU, Taiwan A research team led by Dr. Yunching Chen and Tsai-Te Lu of National Tsing Hua University have recently developed a new treatment for cancer, in which blood vessels within malignant...
View ArticleClik here to view.
Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and...
DUBLIN & CAMBRIDGE, United Kingdom & BRISBANE, Australia Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation,...
View ArticleClik here to view.
Harbour BioMed Receives U.S. FDA IND Approval for Phase 2 Clinical Trial and...
CAMBRIDGE, Mass. & ROTTERDAM, Netherlands & SUZHOU, China Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND)...
View ArticleClik here to view.
Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation...
CAMBRIDGE, Mass. & ROTTERDAM, Netherlands & SUZHOU, China Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND)...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human...
View ArticleClik here to view.
武田薬品が一部の一般用医薬品およびノンコア資産のアシノへの売却を完了
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502/NYSE:TAK）（「武田薬品」）は本日、当社グロース＆エマージング マーケッツ ビジネス ユニット（GEM...
View ArticleClik here to view.
武田完成向Acino出售部分非处方药和非核心资产的交易
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布已完成其先前宣布的一项交易，即以逾2亿美元的总价值向Acino出售其增长与新兴市场业务部门(GEM...
View ArticleClik here to view.
武田同意以8.25亿美元向Hypera Pharma出让拉丁美洲部分非处方和非核心资产
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)（“武田”）今天宣布，其已达成一项协议，将以8.25亿美元总价值将其位于拉丁美洲的专有部分非核心产品组合出让给在品牌处方、消费者健康和品牌仿制药领域处于领先地位的巴西最大制药公司Hypera S.A. (“Hypera...
View ArticleClik here to view.